Monday Educational Symposia during the ISPOR 12th European Congress

Monday, 26 October 2009 7:00-8:00

Comparative Effectiveness: Can the Agencies’ Demands Be Met?

As decision-makers and the citizens they serve demand stronger evidence to support coverage, prioritization, and pricing, the need for comparative effectiveness research has come to the fore. Traditional clinical trial designs provide valid data but are extremely expensive and time consuming, making them not very practical. Even if everybody agrees that better information on relative effectiveness is required for improving the quality of health care decisions, the entities involved have not identified a common approach to this new challenge.

This symposium will explore the views of three major agencies (NICE, HAS and IQWiG) involved in evaluating new products on the requirements for this type of data. What methods will they find acceptable? Which ones not? How soon does the information need to be available? Who can collect it? Who should collect it? What about funding? What is the role of various stakeholders? What changes are expected? Is simulation the solution? Is it possible to develop a unified approach? Is it desirable? We will open up the symposium for discussion of the advantages of various methods, the challenges, the future trends and possible implications.

Symposium Presentation

For Proceedings, Email: analytics@unitedbiosource.com

Moderator:
J. Jaime Caro MDCM, FRCPC, FACP, Senior Vice-President of Health Economics, United BioSource Corporation, Lexington, MA, USA

Speakers:
Kalipso Chalkidou MD, PhD, Director, National Institute for Health and Clinical Excellence (NICE), London, UK

Andreas Gerber MD, PhD, MA, MSc, Head of Health Economics Department, Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), Cologne, Germany

Claire Le Jeunne MD, PhD,  Vice President, Haute Autorité de Santé (HAS), Paris, France

Sponsored by UBC and Shire

Monday Educational Symposia during the ISPOR 12th European Congress

Monday 26 October 2009 12:45-13:45

New Developments in Health Technology Assessment (HTA): How Does This Impact Health Economics and Outcomes Research?

This symposium will provide an update on global trends in health technology assessment (HTA), likely future development and how this is going to affect health economics and outcomes research. Specific focus will be on potential changes in US health care decision making (comparative effectiveness research and health reform) and key implications of these trends for drugs in development. Changes in the way health economics research is being conducted and opportunities for innovative commercialization strategies to meet these needs will be presented.

12.45 – 12.50		Introduction
		Jonothan Tierce C.Phil, General Manager and Center of Excellence Leader Global Health Economics & Outcomes Research, IMS Health, Falls Church, VA, USA
12.50 – 13.10		Comparative Effectiveness Research in the US – implications for Health Economics and Outcomes Research
		Joshua S. Benner PharmD, ScD, Research Director, Engelberg Center for Health Care Reform/Brookings Institution Adjunct Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Pennsylvania, PA, USA
13.10 – 13.30		Implications of the US Health Reform for the pharmaceutical industry
		Murray Aitken MBA, Senior Vice President, Healthcare Insights, IMS Health, Norwalk, CT, USA
13.30 – 13.45		Q & A

Sponsored by IMS Health